ArticleTherapeutic advances in gastroenterology2021

A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study.

Brigida Barberio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.